Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device
- Targeting ADC and Cell & Gene Therapy Customers - WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of TangenX® SC, the industry’s first holder-free, self-contained Tangential Flow Filtration (TFF) device. The technology is especially suited to the manufacture of biologics where fully closed systems are critical or ideal, including antibody drug conjugates (ADCs), viral vectors, nucleic acids and lipid nanoparticles, and can also be applied to monoclonal antibody, and recombinant protein production. TangenX SC is not only transformative, it is also a milestone achievement in the advancement of downstream flat sheet TFF technology for ultrafiltration and diafiltration (UF/DF), which is performed in nearly every biopharmaceutical manufacturing process to concentrate and purify drug. Christine Gebski, Senior Vice President, Filtration and
